Skip to content

Trial Summary

Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer

A phase I/ II, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of AGEN2034 in subjects with metastatic or locally advanced solid tumours, with expansion to second line cervical cancer.

Acronym:

AGENUS

ACTRN/NCT /ethics:

NCT03104699

Scientific title:

Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Sponsor / Cooperative group:

Agenus Inc.

Trial & Patient Characteristics

Cancer TypeGynaecological
Trial TypeTreatment
PhasePhase I, Phase II
Age Range18+ years
SexFemale
Tumour StreamCervical
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2019-09-01
Anticipated End Date-

Participating Hospitals

HospitalCalvary North Adelaide Hospital
Clinical Trial CoordinatorJulie Rowe
Emailjulie.rowe@calvarycare.org.au
Phone08 8239 9536
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusRecruiting